Stocktoria
Aquestive Therapeutics, Inc. AQST
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-07-25
Aquestive Therapeutics, Inc. statistics & valuation
Market cap$550.7M
P / S12.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -159.5% | -53.5% | -29.9% | -88.2% | -68.2% |
| Net margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% |
| FCF margin | -119.0% | -62.4% | -14.6% | -22.7% | -66.7% |
| Return on assets | -52.2% | -43.5% | -13.7% | -95.3% | -113.8% |
| Return on equity | 248.9% | 73.4% | 7.4% | 45.9% | 85.9% |
| Debt / equity | -1.34× | -0.75× | -0.42× | — | — |
| Current ratio | 3.14 | 4.68 | 2.24 | 1.01 | 2.15 |
| Revenue growth | -22.6% | 13.8% | 6.1% | -6.2% | 10.9% |
Source: SEC EDGAR filings · CIK 0001398733 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.